nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—SELE—vein—intracranial aneurysm	0.0753	0.146	CbGeAlD
Carvedilol—VCAM1—vein—intracranial aneurysm	0.0693	0.135	CbGeAlD
Carvedilol—NPPB—artery—intracranial aneurysm	0.0454	0.0883	CbGeAlD
Carvedilol—SELE—artery—intracranial aneurysm	0.0307	0.0597	CbGeAlD
Carvedilol—VCAM1—artery—intracranial aneurysm	0.0282	0.0549	CbGeAlD
Carvedilol—HIF1A—artery—intracranial aneurysm	0.0272	0.0528	CbGeAlD
Carvedilol—GJA1—artery—intracranial aneurysm	0.0263	0.0512	CbGeAlD
Carvedilol—HIF1A—brainstem—intracranial aneurysm	0.0116	0.0225	CbGeAlD
Carvedilol—GJA1—brainstem—intracranial aneurysm	0.0112	0.0218	CbGeAlD
Carvedilol—SELE—medulla oblongata—intracranial aneurysm	0.00911	0.0177	CbGeAlD
Carvedilol—VCAM1—medulla oblongata—intracranial aneurysm	0.00838	0.0163	CbGeAlD
Carvedilol—SELE—midbrain—intracranial aneurysm	0.00833	0.0162	CbGeAlD
Carvedilol—HIF1A—medulla oblongata—intracranial aneurysm	0.00806	0.0157	CbGeAlD
Carvedilol—GJA1—medulla oblongata—intracranial aneurysm	0.00782	0.0152	CbGeAlD
Carvedilol—NPPB—brain—intracranial aneurysm	0.00775	0.0151	CbGeAlD
Carvedilol—VCAM1—midbrain—intracranial aneurysm	0.00766	0.0149	CbGeAlD
Carvedilol—HIF1A—midbrain—intracranial aneurysm	0.00737	0.0143	CbGeAlD
Carvedilol—GJA1—midbrain—intracranial aneurysm	0.00715	0.0139	CbGeAlD
Carvedilol—NDUFC2—medulla oblongata—intracranial aneurysm	0.00681	0.0132	CbGeAlD
Carvedilol—SELE—cerebellum—intracranial aneurysm	0.00644	0.0125	CbGeAlD
Carvedilol—NDUFC2—midbrain—intracranial aneurysm	0.00622	0.0121	CbGeAlD
Carvedilol—HIF1A—cerebellum—intracranial aneurysm	0.0057	0.0111	CbGeAlD
Carvedilol—PTGS1—artery—intracranial aneurysm	0.00559	0.0109	CbGeAlD
Carvedilol—GJA1—cerebellum—intracranial aneurysm	0.00553	0.0108	CbGeAlD
Carvedilol—SELE—brain—intracranial aneurysm	0.00523	0.0102	CbGeAlD
Carvedilol—NDUFC2—cerebellum—intracranial aneurysm	0.00481	0.00936	CbGeAlD
Carvedilol—VCAM1—brain—intracranial aneurysm	0.00481	0.00936	CbGeAlD
Carvedilol—HIF1A—brain—intracranial aneurysm	0.00463	0.009	CbGeAlD
Carvedilol—GJA1—brain—intracranial aneurysm	0.00449	0.00873	CbGeAlD
Carvedilol—VEGFA—cerebellum—intracranial aneurysm	0.00437	0.00849	CbGeAlD
Carvedilol—NDUFC2—brain—intracranial aneurysm	0.00391	0.0076	CbGeAlD
Carvedilol—VEGFA—brain—intracranial aneurysm	0.00355	0.0069	CbGeAlD
Carvedilol—ADRA1A—brainstem—intracranial aneurysm	0.00332	0.00646	CbGeAlD
Carvedilol—VCAM1—Extracellular matrix organization—TIMP1—intracranial aneurysm	0.0033	0.00679	CbGpPWpGaD
Carvedilol—ADRA1A—Endothelin Pathways—EDNRA—intracranial aneurysm	0.00329	0.00677	CbGpPWpGaD
Carvedilol—VEGFA—Platelet degranulation—TIMP1—intracranial aneurysm	0.00328	0.00675	CbGpPWpGaD
Carvedilol—HIF1A—AGE/RAGE pathway—MMP9—intracranial aneurysm	0.0032	0.00659	CbGpPWpGaD
Carvedilol—GJA1—Corticotropin-releasing hormone—NOS3—intracranial aneurysm	0.00317	0.00654	CbGpPWpGaD
Carvedilol—GJA1—AP-1 transcription factor network—MMP9—intracranial aneurysm	0.00317	0.00652	CbGpPWpGaD
Carvedilol—VEGFA—Response to elevated platelet cytosolic Ca2+—TIMP1—intracranial aneurysm	0.00312	0.00643	CbGpPWpGaD
Carvedilol—VEGFA—Angiogenesis—MMP9—intracranial aneurysm	0.0031	0.00639	CbGpPWpGaD
Carvedilol—HIF1A—AP-1 transcription factor network—MMP9—intracranial aneurysm	0.00306	0.00629	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—SLC25A16—intracranial aneurysm	0.00298	0.00613	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—TIMP1—intracranial aneurysm	0.00297	0.00612	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—CCL2—intracranial aneurysm	0.00292	0.00601	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—NCF1—intracranial aneurysm	0.00282	0.00581	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—STARD13—intracranial aneurysm	0.00277	0.0057	CbGpPWpGaD
Carvedilol—HIF1A—Disease—SLC25A16—intracranial aneurysm	0.00274	0.00564	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—NCF1—intracranial aneurysm	0.00266	0.00548	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CTSS—intracranial aneurysm	0.00243	0.005	CbGpPWpGaD
Carvedilol—ADRA1B—brain—intracranial aneurysm	0.00237	0.00461	CbGeAlD
Carvedilol—ADRA1D—brain—intracranial aneurysm	0.00232	0.00451	CbGeAlD
Carvedilol—KCNH2—medulla oblongata—intracranial aneurysm	0.00224	0.00435	CbGeAlD
Carvedilol—VCAM1—Adaptive Immune System—CTSK—intracranial aneurysm	0.00223	0.0046	CbGpPWpGaD
Carvedilol—ADRA2C—medulla oblongata—intracranial aneurysm	0.00221	0.00429	CbGeAlD
Carvedilol—GJA1—Myometrial Relaxation and Contraction Pathways—NOS3—intracranial aneurysm	0.00209	0.00431	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—MMP9—intracranial aneurysm	0.00209	0.0043	CbGpPWpGaD
Carvedilol—KCNH2—midbrain—intracranial aneurysm	0.00205	0.00398	CbGeAlD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—CST3—intracranial aneurysm	0.00204	0.0042	CbGpPWpGaD
Carvedilol—ADRA2C—midbrain—intracranial aneurysm	0.00202	0.00392	CbGeAlD
Carvedilol—GJA1—EGF/EGFR Signaling Pathway—NOS3—intracranial aneurysm	0.00202	0.00416	CbGpPWpGaD
Carvedilol—ADRA1D—GPCRs, Other—EDNRA—intracranial aneurysm	0.00198	0.00408	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—ASAH1—intracranial aneurysm	0.00197	0.00406	CbGpPWpGaD
Carvedilol—CYP2D6—brainstem—intracranial aneurysm	0.00196	0.00381	CbGeAlD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—CCL2—intracranial aneurysm	0.00196	0.00403	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—NOS3—intracranial aneurysm	0.00191	0.00393	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CTSB—intracranial aneurysm	0.00185	0.00381	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—NCF1—intracranial aneurysm	0.00184	0.00379	CbGpPWpGaD
Carvedilol—XDH—Selenium Micronutrient Network—CCL2—intracranial aneurysm	0.0018	0.00371	CbGpPWpGaD
Carvedilol—ADRB1—Endothelin Pathways—NOS3—intracranial aneurysm	0.00178	0.00367	CbGpPWpGaD
Carvedilol—ADRB2—GPCRs, Other—EDNRA—intracranial aneurysm	0.00176	0.00363	CbGpPWpGaD
Carvedilol—ADRA2A—medulla oblongata—intracranial aneurysm	0.00176	0.00343	CbGeAlD
Carvedilol—CYP2E1—medulla oblongata—intracranial aneurysm	0.00172	0.00335	CbGeAlD
Carvedilol—ADRB1—brain—intracranial aneurysm	0.00168	0.00327	CbGeAlD
Carvedilol—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—intracranial aneurysm	0.00168	0.00346	CbGpPWpGaD
Carvedilol—ADRA1A—cerebellum—intracranial aneurysm	0.00164	0.00319	CbGeAlD
Carvedilol—ADRA2A—midbrain—intracranial aneurysm	0.00161	0.00313	CbGeAlD
Carvedilol—VCAM1—Extracellular matrix organization—MMP2—intracranial aneurysm	0.00159	0.00327	CbGpPWpGaD
Carvedilol—KCNH2—cerebellum—intracranial aneurysm	0.00158	0.00308	CbGeAlD
Carvedilol—ADRA2C—cerebellum—intracranial aneurysm	0.00156	0.00304	CbGeAlD
Carvedilol—VCAM1—Immune System—CTSS—intracranial aneurysm	0.00147	0.00303	CbGpPWpGaD
Carvedilol—VEGFA—Platelet activation, signaling and aggregation—TIMP1—intracranial aneurysm	0.00145	0.00299	CbGpPWpGaD
Carvedilol—ADRA1A—Endothelin Pathways—NOS3—intracranial aneurysm	0.00144	0.00297	CbGpPWpGaD
Carvedilol—VEGFA—Endochondral Ossification—MMP9—intracranial aneurysm	0.00142	0.00292	CbGpPWpGaD
Carvedilol—VEGFA—EPH-Ephrin signaling—MMP2—intracranial aneurysm	0.00139	0.00285	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CTSK—intracranial aneurysm	0.00136	0.00279	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—NOS3—intracranial aneurysm	0.00134	0.00276	CbGpPWpGaD
Carvedilol—ADRA1A—brain—intracranial aneurysm	0.00133	0.00259	CbGeAlD
Carvedilol—ADRB3—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.00132	0.00272	CbGpPWpGaD
Carvedilol—KCNH2—brain—intracranial aneurysm	0.00129	0.0025	CbGeAlD
Carvedilol—ADRA2C—brain—intracranial aneurysm	0.00127	0.00247	CbGeAlD
Carvedilol—ADRA2A—cerebellum—intracranial aneurysm	0.00125	0.00242	CbGeAlD
Carvedilol—CYP2E1—cerebellum—intracranial aneurysm	0.00122	0.00237	CbGeAlD
Carvedilol—ADRB3—Signaling Pathways—STARD13—intracranial aneurysm	0.0012	0.00247	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—STARD13—intracranial aneurysm	0.00119	0.00246	CbGpPWpGaD
Carvedilol—VCAM1—Extracellular matrix organization—MMP9—intracranial aneurysm	0.00119	0.00245	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—NOS3—intracranial aneurysm	0.00117	0.00241	CbGpPWpGaD
Carvedilol—XDH—Metabolism—SLC25A16—intracranial aneurysm	0.00116	0.00239	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.00113	0.00233	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CTSB—intracranial aneurysm	0.00112	0.00231	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—NCF1—intracranial aneurysm	0.00112	0.0023	CbGpPWpGaD
Carvedilol—ADRA1D—G alpha (q) signalling events—EDNRA—intracranial aneurysm	0.00111	0.00229	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—NOS3—intracranial aneurysm	0.0011	0.00227	CbGpPWpGaD
Carvedilol—CYP1A1—brain—intracranial aneurysm	0.00109	0.00211	CbGeAlD
Carvedilol—HIF1A—Disease—CST3—intracranial aneurysm	0.00105	0.00216	CbGpPWpGaD
Carvedilol—VEGFA—EPH-Ephrin signaling—MMP9—intracranial aneurysm	0.00104	0.00214	CbGpPWpGaD
Carvedilol—ADRA1B—LPA receptor mediated events—MMP2—intracranial aneurysm	0.00102	0.0021	CbGpPWpGaD
Carvedilol—ADRA2A—brain—intracranial aneurysm	0.00101	0.00197	CbGeAlD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—intracranial aneurysm	0.000995	0.00205	CbGpPWpGaD
Carvedilol—CYP2E1—brain—intracranial aneurysm	0.00099	0.00193	CbGeAlD
Carvedilol—ABCB1—medulla oblongata—intracranial aneurysm	0.000982	0.00191	CbGeAlD
Carvedilol—CYP2D6—cerebellum—intracranial aneurysm	0.000965	0.00188	CbGeAlD
Carvedilol—PTGS1—brain—intracranial aneurysm	0.000954	0.00185	CbGeAlD
Carvedilol—ADRA1B—G alpha (q) signalling events—EDNRA—intracranial aneurysm	0.000924	0.0019	CbGpPWpGaD
Carvedilol—HIF1A—Disease—NCF1—intracranial aneurysm	0.000913	0.00188	CbGpPWpGaD
Carvedilol—ABCB1—midbrain—intracranial aneurysm	0.000898	0.00174	CbGeAlD
Carvedilol—ADRB3—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000862	0.00177	CbGpPWpGaD
Carvedilol—ADRA1D—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.00086	0.00177	CbGpPWpGaD
Carvedilol—ADRA2B—Platelet activation, signaling and aggregation—TIMP1—intracranial aneurysm	0.000857	0.00176	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—CCL2—intracranial aneurysm	0.000844	0.00174	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—intracranial aneurysm	0.000826	0.0017	CbGpPWpGaD
Carvedilol—ADRA1A—G alpha (q) signalling events—EDNRA—intracranial aneurysm	0.00082	0.00169	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.00081	0.00167	CbGpPWpGaD
Carvedilol—ADRA2C—Platelet activation, signaling and aggregation—TIMP1—intracranial aneurysm	0.0008	0.00165	CbGpPWpGaD
Carvedilol—CYP2D6—brain—intracranial aneurysm	0.000784	0.00152	CbGeAlD
Carvedilol—ADRB1—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.000784	0.00161	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—STARD13—intracranial aneurysm	0.00078	0.00161	CbGpPWpGaD
Carvedilol—ADRA2B—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.000777	0.0016	CbGpPWpGaD
Carvedilol—XDH—Metabolism—ASAH1—intracranial aneurysm	0.00077	0.00159	CbGpPWpGaD
Carvedilol—ADRA1B—LPA receptor mediated events—MMP9—intracranial aneurysm	0.000767	0.00158	CbGpPWpGaD
Carvedilol—ADRB2—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.000767	0.00158	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TIMP1—intracranial aneurysm	0.000749	0.00154	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000737	0.00152	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—intracranial aneurysm	0.000734	0.00151	CbGpPWpGaD
Carvedilol—ADRA2C—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.000725	0.00149	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—AGER—intracranial aneurysm	0.000724	0.00149	CbGpPWpGaD
Carvedilol—ADRA1B—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.000714	0.00147	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—STARD13—intracranial aneurysm	0.000711	0.00146	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—STARD13—intracranial aneurysm	0.000704	0.00145	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—STARD13—intracranial aneurysm	0.000695	0.00143	CbGpPWpGaD
Carvedilol—ABCB1—cerebellum—intracranial aneurysm	0.000694	0.00135	CbGeAlD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000672	0.00138	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000665	0.00137	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—STARD13—intracranial aneurysm	0.000658	0.00135	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000657	0.00135	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—TIMP1—intracranial aneurysm	0.00065	0.00134	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—STARD13—intracranial aneurysm	0.000647	0.00133	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NCF1—intracranial aneurysm	0.00064	0.00132	CbGpPWpGaD
Carvedilol—ADRA1A—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.000634	0.00131	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—intracranial aneurysm	0.000631	0.0013	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000622	0.00128	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000612	0.00126	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EDNRA—intracranial aneurysm	0.000604	0.00124	CbGpPWpGaD
Carvedilol—ADRA2A—GPCRs, Class A Rhodopsin-like—EDNRA—intracranial aneurysm	0.000589	0.00121	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—STARD13—intracranial aneurysm	0.000575	0.00118	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.00057	0.00117	CbGpPWpGaD
Carvedilol—ABCB1—brain—intracranial aneurysm	0.000564	0.0011	CbGeAlD
Carvedilol—ADRA1D—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000561	0.00116	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000558	0.00115	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—SLC25A16—intracranial aneurysm	0.000545	0.00112	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—SLC25A16—intracranial aneurysm	0.000544	0.00112	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000543	0.00112	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—STARD13—intracranial aneurysm	0.000534	0.0011	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—MMP2—intracranial aneurysm	0.000515	0.00106	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000511	0.00105	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000507	0.00104	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDNRA—intracranial aneurysm	0.000505	0.00104	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—EDNRA—intracranial aneurysm	0.0005	0.00103	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000487	0.001	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000473	0.000975	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000466	0.000959	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—SLC25A16—intracranial aneurysm	0.000443	0.000912	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000442	0.00091	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TIMP1—intracranial aneurysm	0.000442	0.000909	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000426	0.000876	CbGpPWpGaD
Carvedilol—ADRB3—GPCR ligand binding—CCL2—intracranial aneurysm	0.000425	0.000874	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000414	0.000852	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TIMP1—intracranial aneurysm	0.000412	0.000849	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—NOS3—intracranial aneurysm	0.000412	0.000847	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—SLC25A16—intracranial aneurysm	0.000407	0.000838	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—MMP9—intracranial aneurysm	0.000387	0.000797	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—EDNRA—intracranial aneurysm	0.000384	0.000792	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—SLC25A16—intracranial aneurysm	0.000383	0.00079	CbGpPWpGaD
Carvedilol—HIF1A—Disease—NOS3—intracranial aneurysm	0.000379	0.00078	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—MMP2—intracranial aneurysm	0.000367	0.000757	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—ASAH1—intracranial aneurysm	0.000364	0.000749	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000363	0.000748	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—ASAH1—intracranial aneurysm	0.000361	0.000744	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—ASAH1—intracranial aneurysm	0.000361	0.000742	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—NOS3—intracranial aneurysm	0.000338	0.000695	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TIMP1—intracranial aneurysm	0.000335	0.00069	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000331	0.000681	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000328	0.000675	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000324	0.000667	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000317	0.000653	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000306	0.000631	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—SLC25A16—intracranial aneurysm	0.000306	0.000631	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000301	0.000621	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—CCL2—intracranial aneurysm	0.000298	0.000613	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—ASAH1—intracranial aneurysm	0.000293	0.000604	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000289	0.000595	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—SLC25A16—intracranial aneurysm	0.000289	0.000594	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000288	0.000593	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000286	0.00059	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—SLC25A16—intracranial aneurysm	0.000286	0.000589	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000283	0.000582	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NCF1—intracranial aneurysm	0.000277	0.00057	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—CCL2—intracranial aneurysm	0.000277	0.00057	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—MMP9—intracranial aneurysm	0.000276	0.000569	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NCF1—intracranial aneurysm	0.000276	0.000568	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—ASAH1—intracranial aneurysm	0.000269	0.000555	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000268	0.000551	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000267	0.000551	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NOS3—intracranial aneurysm	0.000265	0.000546	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000263	0.000542	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000262	0.00054	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EDNRA—intracranial aneurysm	0.000261	0.000538	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EDNRA—intracranial aneurysm	0.000261	0.000537	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EDNRA—intracranial aneurysm	0.00026	0.000535	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000257	0.000529	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—ASAH1—intracranial aneurysm	0.000254	0.000523	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—CCL2—intracranial aneurysm	0.000252	0.000519	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—CCL2—intracranial aneurysm	0.00025	0.000514	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—intracranial aneurysm	0.000249	0.000512	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—CCL2—intracranial aneurysm	0.000246	0.000508	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—SLC25A16—intracranial aneurysm	0.000244	0.000503	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000243	0.0005	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000239	0.000492	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000234	0.000482	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—CCL2—intracranial aneurysm	0.000233	0.00048	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—CCL2—intracranial aneurysm	0.00023	0.000473	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—CCL2—intracranial aneurysm	0.000218	0.000449	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—EDNRA—intracranial aneurysm	0.000217	0.000447	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—MMP9—intracranial aneurysm	0.000213	0.000438	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000212	0.000437	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—CCL2—intracranial aneurysm	0.000204	0.00042	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—ASAH1—intracranial aneurysm	0.000203	0.000418	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—NOS3—intracranial aneurysm	0.000199	0.00041	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EDNRA—intracranial aneurysm	0.000197	0.000406	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—ASAH1—intracranial aneurysm	0.000191	0.000394	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—ASAH1—intracranial aneurysm	0.00019	0.00039	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—CCL2—intracranial aneurysm	0.000189	0.00039	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—SLC25A16—intracranial aneurysm	0.000189	0.000389	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—NOS3—intracranial aneurysm	0.000186	0.000383	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NCF1—intracranial aneurysm	0.00018	0.000371	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EDNRA—intracranial aneurysm	0.00017	0.00035	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NCF1—intracranial aneurysm	0.000164	0.000338	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NCF1—intracranial aneurysm	0.000163	0.000335	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—ASAH1—intracranial aneurysm	0.000162	0.000334	CbGpPWpGaD
Carvedilol—XDH—Metabolism—NOS3—intracranial aneurysm	0.000161	0.000331	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NCF1—intracranial aneurysm	0.000161	0.000331	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EDNRA—intracranial aneurysm	0.000155	0.000319	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EDNRA—intracranial aneurysm	0.000154	0.000316	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NCF1—intracranial aneurysm	0.000152	0.000313	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EDNRA—intracranial aneurysm	0.000152	0.000312	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NOS3—intracranial aneurysm	0.000151	0.000311	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NCF1—intracranial aneurysm	0.00015	0.000308	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EDNRA—intracranial aneurysm	0.000143	0.000295	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CCL2—intracranial aneurysm	0.000142	0.000292	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EDNRA—intracranial aneurysm	0.000141	0.000291	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NCF1—intracranial aneurysm	0.000133	0.000274	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CCL2—intracranial aneurysm	0.000129	0.000266	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CCL2—intracranial aneurysm	0.000129	0.000265	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CCL2—intracranial aneurysm	0.000128	0.000264	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CCL2—intracranial aneurysm	0.000128	0.000264	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CCL2—intracranial aneurysm	0.000126	0.00026	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EDNRA—intracranial aneurysm	0.000125	0.000258	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—ASAH1—intracranial aneurysm	0.000125	0.000257	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NCF1—intracranial aneurysm	0.000123	0.000254	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CCL2—intracranial aneurysm	0.00012	0.000246	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CCL2—intracranial aneurysm	0.000118	0.000243	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EDNRA—intracranial aneurysm	0.000117	0.00024	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NOS3—intracranial aneurysm	0.000115	0.000236	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NOS3—intracranial aneurysm	0.000114	0.000236	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CCL2—intracranial aneurysm	0.000105	0.000215	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CCL2—intracranial aneurysm	9.72e-05	0.0002	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—MMP9—intracranial aneurysm	9.2e-05	0.00019	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—MMP9—intracranial aneurysm	9.18e-05	0.000189	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CCL2—intracranial aneurysm	8.38e-05	0.000173	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CCL2—intracranial aneurysm	7.64e-05	0.000157	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CCL2—intracranial aneurysm	7.57e-05	0.000156	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—NOS3—intracranial aneurysm	7.54e-05	0.000155	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—NOS3—intracranial aneurysm	7.52e-05	0.000155	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NOS3—intracranial aneurysm	7.47e-05	0.000154	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CCL2—intracranial aneurysm	7.47e-05	0.000154	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CCL2—intracranial aneurysm	7.07e-05	0.000146	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CCL2—intracranial aneurysm	6.96e-05	0.000143	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NOS3—intracranial aneurysm	6.81e-05	0.00014	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NOS3—intracranial aneurysm	6.75e-05	0.000139	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NOS3—intracranial aneurysm	6.66e-05	0.000137	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NOS3—intracranial aneurysm	6.3e-05	0.00013	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NOS3—intracranial aneurysm	6.2e-05	0.000128	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CCL2—intracranial aneurysm	6.18e-05	0.000127	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—NOS3—intracranial aneurysm	6.12e-05	0.000126	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—MMP9—intracranial aneurysm	6e-05	0.000123	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CCL2—intracranial aneurysm	5.74e-05	0.000118	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—NOS3—intracranial aneurysm	5.62e-05	0.000116	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NOS3—intracranial aneurysm	5.51e-05	0.000113	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—MMP9—intracranial aneurysm	5.46e-05	0.000112	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—MMP9—intracranial aneurysm	5.41e-05	0.000111	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—MMP9—intracranial aneurysm	5.34e-05	0.00011	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—NOS3—intracranial aneurysm	5.3e-05	0.000109	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NOS3—intracranial aneurysm	5.12e-05	0.000105	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—MMP9—intracranial aneurysm	5.06e-05	0.000104	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—MMP9—intracranial aneurysm	4.98e-05	0.000102	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—MMP9—intracranial aneurysm	4.42e-05	9.1e-05	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—NOS3—intracranial aneurysm	4.23e-05	8.72e-05	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—MMP9—intracranial aneurysm	4.11e-05	8.46e-05	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—NOS3—intracranial aneurysm	3.99e-05	8.21e-05	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—NOS3—intracranial aneurysm	3.95e-05	8.14e-05	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—NOS3—intracranial aneurysm	3.38e-05	6.96e-05	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—NOS3—intracranial aneurysm	2.61e-05	5.37e-05	CbGpPWpGaD
